About The Study: According to the results of this population-based surveillance study, during 2024-2025, both maternal respiratory syncytial virus (RSV) vaccine and nirsevimab were estimated to be effective at protecting infants from RSV-associated hospitalizations in their first RSV season, and RSV-associated hospitalization rates in newborns and infants ages 0 to 11 months were reduced by up to half compared to seasons before these products were introduced.
Corresponding Author: To contact the corresponding author, Heidi L. Moline, MD, MPH, email ick6@cdc.gov .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2025.5778)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.5778?guestAccessKey=b72ce1b3-d8d4-4d7c-868c-48267499f87a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122225
JAMA Pediatrics